Scarica l'app Stockscreener
1.15
2.68%
0.03
Dopo l'orario di chiusura:
1.14
-0.01
-0.87%
Panoramica
Notizia
Cronologia dei prezzi
Financials
Perché ALZN Giù?
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$1.12
Aprire:
$1.11
Volume 24 ore:
88,954
Relative Volume:
0.69
Capitalizzazione di mercato:
$6.25M
Reddito:
-
Utile/perdita netta:
$-5.85M
Rapporto P/E:
-0.172
EPS:
-6.6877
Flusso di cassa netto:
$-8.00M
1 W Prestazione:
-2.54%
1M Prestazione:
-4.17%
6M Prestazione:
-66.18%
1 anno Prestazione:
-86.82%
Intervallo 1D:
$1.1071
$1.16
Intervallo di 1 settimana:
$1.10
$1.2048
Portata 52W:
$1.06
$15.06
Alzamend Neuro Inc Stock (ALZN) Company Profile
Nome
Alzamend Neuro Inc
Settore
Industria
Telefono
844-722-6333
Indirizzo
3500 LENOX RD. NE, ATLANTA
Confronta ALZN con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ALZN
Alzamend Neuro Inc
|
1.15 | 6.25M | 0 | -5.85M | -8.00M | -6.6877 |
|
VRTX
Vertex Pharmaceuticals Inc
|
438.40 | 113.67B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
683.08 | 74.97B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
665.68 | 40.50B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
277.16 | 35.95B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
120.88 | 29.63B | 3.30B | -501.07M | 1.03B | -2.1146 |
Alzamend Neuro Inc Stock (ALZN) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2021-10-01 | Iniziato | Ascendiant Capital Markets | Buy |
Alzamend Neuro Inc Borsa (ALZN) Ultime notizie
Alzamend Neuro, Inc. (NASDAQ:ALZN) Short Interest Update - Defense World
Has Alzamend Neuro (ALZN) Outpaced Other Medical Stocks This Year? - Yahoo Finance
Alzamend Neuro to Present at the Sequire Investor Summit - Business Wire
Alzamend Neuro CEO to Present Five Phase II Trial Plans at Sequire Investor Summit - StockTitan
Alzamend Neuro to Present Non-Clinical Data Update at the Society of Toxicology 2025 Annual Meeting and ToxExpo - Business Wire
Alzamend Neuro (NASDAQ:ALZN) Price Target Cut to $32.00 by Analysts at Ascendiant Capital Markets - Defense World
Alzamend Neuro Reports Strong Financial Results and Clinical Program Updates - Defense World
Alzamend Neuro says net cash gained by financing activity $8.3M - Yahoo Finance
Alzamend Neuro, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended October 31, 2024 - Marketscreener.com
Alzamend Neuro Reports Second Quarter 2025 Financial Results and Provides Update on Clinical Programs - Business Wire
Alzamend Neuro Secures $25M Financing Deal, Advances Alzheimer's Drug Pipeline Amid Financial Turnaround - StockTitan
Alzamend Neuro Inc. (ALZN) reports earnings - Quartz
Alzamend Neuro stock hits 52-week low at $1.24 amid market challenges - Investing.com Nigeria
Alzamend reports promising results for brain-targeted lithium therapy - Investing.com India
Alzamend Neuro Announces Full Data Set from its Nonclinical Study: Comparing Brain and Plasma Lithium Exposures between AL001 and Lithium Carbonate in Alzheimer’s Transgenic Mice - Business Wire
EXCLUSIVE: Alzamend Neuro Reveals Full Data From Nonclinical Study Of Its Lead Alzheimer's Drug Potential - Yahoo Finance
Alzamend Neuro stock hits 52-week low at $1.39 amid sharp decline - Investing.com
Alzamend Neuro sets trial dosage for AL001 lithium therapy - Alzheimer's News Today
Alzamend Neuro Announces Full Data Set from Phase IIA Multiple Ascending Dose Clinical Trial for AL001 Treatment of Dementia Related to Alzheimer’s - BioSpace
Alzamend Neuro advances Alzheimer's treatment with new lithium dose - Investing.com
Alzamend Neuro advances Alzheimer's treatment with new lithium dose By Investing.com - Investing.com South Africa
EXCLUSIVE: Alzamend Neuro Reveals Full Data Set From Multiple Ascending Dose Trial For Lead Candidate For Dementia Related to Alzheimer's - Yahoo Finance
Alzamend Neuro Inc (ALZN) receives a Buy rating from Ascendiant Capital Markets - Knox Daily
Alzamend Neuro Inc (ALZN) Performance and Fundamentals Dashboard tells a completely different story - SETE News
Alzamend Neuro Inc (ALZN-Q) QuotePress Release - The Globe and Mail
Alzamend Neuro regains Nasdaq compliance with equity rule By Investing.com - Investing.com UK
Alzamend Neuro Regains Compliance with Nasdaq Listing Standards - StockTitan
Alzamend Neuro (ALZN) Price Target Decreased by 16.00% to 21.42 - MSN
Alzamend Neuro CEO Stephan Jackman to Participate in the Maxim Group’s Virtual Healthcare Conference - Barchart
Nasdaq Bank Index (BANK) QuotePress Release - The Globe and Mail
TSX Venture Composite Index (JX) QuotePress Release - The Globe and Mail
Alzamend Neuro enters agreement for $6.5 million ATM offering - Investing.com India
Alzamend Neuro enters agreement for $6.5 million ATM offering By Investing.com - Investing.com Australia
Globalfoundries Inc (GFS-Q) QuotePress Release - The Globe and Mail
Why Nikola Shares Are Trading Lower By Around 10%? Here Are Other Stocks Moving In Monday's Mid-Day Session - MSN
A Guide To The Risks Of Investing In Alzamend Neuro Inc (ALZN) - Knox Daily
Alzamend Neuro Inc: Rising -96.02% from 52-Week Low, Can the Stock Stay Afloat? - The InvestChronicle
Alzamend Neuro stock hits 52-week low at $1.81 amid market challenges - Investing.com
Understanding the Risks of Investing in Alzamend Neuro Inc (ALZN) - Knox Daily
New partners team up for Phase 2 trial of novel lithium therapy AL001 - Alzheimer's News Today
Ratios Reveal: Breaking Down Alzamend Neuro Inc (ALZN)’s Financial Health - The Dwinnex
Keeping an Eye on Alzamend Neuro Inc (ALZN) After Insider Trading Activity - Knox Daily
Alzamend Neuro Inc (ALZN) is a good investment, but the stock may be overvalued - US Post News
Alzamend Neuro Inc [ALZN] Records 50-Day SMA of $3.50 - Knox Daily
It is Poised to be a Bull Market for Alzamend Neuro Inc (ALZN) - SETE News
Investing in Alzamend Neuro Inc (ALZN): What You Must Know - Knox Daily
Market Momentum: Alzamend Neuro Inc (ALZN) Registers a -7.47 Decrease, Closing at 2.85 - The Dwinnex
Alzamend partners with Mass General for clinical trials - Investing.com
Examining Alzamend Neuro Inc (ALZN) more closely is necessary - US Post News
Alzamend partners with Mass General for clinical trials By Investing.com - Investing.com UK
Alzamend Neuro Issues Letter to Stockholders - StockTitan
Alzamend Neuro Inc Azioni (ALZN) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
5.49%
0.79%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):